Navigation Links
Addex Achieves Statistically Significant Outcome in Phase IIa,Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease

N = 11 % time pH>4 in 24h 96.5 92.8 0.014 (Primary endpoint) % time pH>4 nocturnal 96.3 90.3 0.0028 Total duration reflux 40 86 0.0132 pH<4 24h (min) Total duration reflux 16.2 48.6 0.0021 pH<4 nocturnal (min) No. symptomatic 1.9 7.0 0.031 episodes Duration symptomatic 5.2 13.9 0.031 episodes (min)

Professor Jan Tack, Professor of Medicine at the Department of Pathophysiology, Gastroenterology Section of the University of Leuven, Belgium, commented: "In spite of the clinical successes of acid-suppressive therapy, there remains a significant unmet need in our ability to manage symptoms of GERD disease. To overcome limitations of acid-suppressive drugs, which eliminate only the acid component of reflux disease, drugs that inhibit reflux events are needed. These results, in keeping with previous animal studies, provide the first confirmation that mGluR5 inhibition is able to significantly reduce reflux events and symptoms in GERD patients. The magnitude of the effect on reflux time and symptoms suggest a potential for ADX10059 to become a major addition to our therapeutic options in GERD."

"ADX10059 is the first compound with this mode of action to have demonstrated significant therapeutic potential in GERD in man," said Dr Vincent Mutel, CEO of Addex. "Brought into clinical trials exactly 2 years after its discovery, it has the potential to become a breakthrough therapy in the management of this very common condition for which there is an important unmet medical need."

About GERD

GERD is estimated to affect 15% of the adult population in the US. The proton pump inhibitors (PPIs) are the market leaders, with annual worldwide sales of approximately $16 billion. Their mechanism of action in GERD is indi
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Addex Reports Positive Results in Phase IIa Clinical Trial With ADX10059 in Migraine
2. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
3. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
4. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
5. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
6. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
7. Mymetics HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model
8. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
9. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
11. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
Post Your Comments:
(Date:5/22/2015)... HILL, N.C. , May 22, 2015 /PRNewswire/ ... be hosting its sixth Medical Affairs ... 12:30PM (EDT) via a virtual roundtable to discuss ... Research." Best Practices, Medical Affairs Consortium ... sharing insights about the key challenges they face. ...
(Date:5/22/2015)... Taskforce representing Canada,s living victims of ... the Minister and Health Canada have put into this program ... of the thalidomide survivors, and more than 70% of them ... annual adjustments for inflation. Certain of the thalidomide ... on the severity of their disability, tax free, with inflation ...
(Date:5/22/2015)... OAKS, Calif. , May 22, 2015 ... announced the Company has commenced termination of ... of brodalumab with AstraZeneca (LON:AZN, STO:AZN and ... IL-17 inhibitor, is in development for patients ... axial spondyloarthritis.  The decision was based on ...
Breaking Medicine Technology:Best Practices Sixth Medical Affairs Consortium Roundtable to Focus on Health Economics & Outcomes Research 2Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5
... CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), developer of the ultra-sensitive ... the In-Vitro Diagnostics (IVD) market, announced today a further update regarding ... one of the largest manufacturers and distributors of magnetic beads for ... , ...
... Tibotec Therapeutics, a division of Centocor Ortho Biotech Products, ... Manager Portal (the Portal), a free, easy-to-use online resource ... providers meet their daily client education and professional needs. The ... the 22nd National Conference on Social Work and HIV/AIDS, the ...
Cached Medicine Technology:CardioGenics Announces Update Regarding Status of Merck Agreement 2CardioGenics Announces Update Regarding Status of Merck Agreement 3Tibotec Therapeutics Debuts Innovative Web Portal for HIV/AIDS Front-Line Service Providers 2Tibotec Therapeutics Debuts Innovative Web Portal for HIV/AIDS Front-Line Service Providers 3Tibotec Therapeutics Debuts Innovative Web Portal for HIV/AIDS Front-Line Service Providers 4
(Date:5/22/2015)... (PRWEB) May 22, 2015 The American ... exciting events in June. They will hold a webinar ... and a two-day class on Classical Chinese Medicine. , ... 3, Dr. Steve Given, the Dean of Clinical Education, ... the new First Professional Doctorate program. ACTCM is currently ...
(Date:5/22/2015)... York, New York (PRWEB) May 22, 2015 ... http://www.xareltolawsuit2015.com/ ) filed on behalf of individuals who ... due to its use continue to move forward ... Louisiana. According to a Pretrial Order dated May ... the preservation of documents and electronically stored information. ...
(Date:5/22/2015)... London, UK (PRWEB) May 22, 2015 ... the leading treatment option for chronic obstructive pulmonary ... UK’s GlaxoSmithKline plc and AstraZeneca plc as well ... for market share and position. But will market ... from the already well-entrenched products to completely new ...
(Date:5/22/2015)... Family, friends, students, colleagues, mentors and fellow ... LaSalle D. Leffall, on Monday, May 18, with an ... Rounds in the hospital’s Tower Auditorium. Leffall’s younger sister, ... trying to keep the secret. “I’d like to go ... he’ll know something is up,” she said. , After ...
(Date:5/22/2015)... LINCOLN, R.I. (PRWEB) May 22, 2015 Memorial ... so Amica Insurance is offering some tips to ... National Safety Council, there will be 383 traffic fatalities this ... tips from the National Highway Traffic Safety Association: , ... everyone in the vehicle is wearing a seatbelt, whether they’re ...
Breaking Medicine News(10 mins):Health News:ACTCM Announces Upcoming June Events 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 3Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 4Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Colleagues Surprise Dr. LaSalle Leffall with 85th Birthday Celebration 2Health News:Amica Has 4 Road Safety Tips for Memorial Day Weekend 2
... NEW YORK, April 28 PSI Corp. (Pink ... its partner in the,Digital Signage Network, has signed ... Network., David Foni, Chairman and CEO of ... and Texas are accretive to PSI,s network in,more ...
... Ala., April 28 HealthSouth Corporation,(NYSE: ... into a definitive agreement,through one of its ... of South Jersey, a 34-bed inpatient rehabilitation,hospital ... Partnership., "We are very pleased to ...
... found measurable gains in those with moderate to severe ... implanting specialized cells found in the human eye into ... were able to reduce symptoms and improve quality of ... The new treatment, dubbed Spheramine, reduced symptoms experienced when ...
... Ten outstanding geriatric social work faculty members have been ... Faculty Scholars Program , a venture funded by the ... The Gerontological Society of America , and directed by ... are provided with opportunities for professional development and $100,000 ...
... cord injuries is hampered by a reliance on animal ... new study in the upcoming edition of the peer-reviewed ... by scientists with the Physicians Committee for Responsible Medicine. ... dont have a drug to cure spinal cord injury ...
... The overall amputation rate in northern Illinois is declining ... disease, new research shows. , But not everyone ... from Northwestern University,s Feinberg School of Medicine has found ... West Side have a five times higher rate of ...
Cached Medicine News:Health News:PSI Corp. Announces Additional Hospitals and Medical Office Buildings to Utilize Its Digital Signage Network 2Health News:HealthSouth to Purchase The Rehabilitation Hospital of South Jersey 2Health News:HealthSouth to Purchase The Rehabilitation Hospital of South Jersey 3Health News:Eye Cell Implants Improve Parkinson's Symptoms 2Health News:Eye Cell Implants Improve Parkinson's Symptoms 3Health News:The Gerontological Society of america Announces 2008 Hartford Faculty Scholars 2Health News:Spinal cord injury research hampered by animal models, says new study 2Health News:African Americans have 5 times higher amputation rate 2
... Laparoscopic Instruments incorporate a layered design unique ... and monitored to prevent stray electrosurgical burns ... by insulation failure or capacitive coupling; a ... built into all AEM Instruments provides a ...
... The 5mm AEM Laparoscopic Instruments incorporate ... AEM Instruments are shielded and monitored to ... of the instrument caused by insulation failure ... risk. The protective shield built into all ...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
... Laparoscopic Instruments incorporate a layered design unique ... and monitored to prevent stray electrosurgical burns ... by insulation failure or capacitive coupling; a ... built into all AEM Instruments provides a ...
Medicine Products: